Headline
The latest stories from AHA Today.
Nearly three-fourths of the 2.4 million U.S. adults who reported using buprenorphine in 2019 did not misuse the medication in the past 12 months, according to a National Institutes of Health study released in JAMA Network Open.
The Food and Drug Administration approved the first interchangeable biosimilar product for Humira, a monoclonal antibody used to treat certain inflammatory diseases.
A symposium hosted by the AHA at the HLTH conference featured a panel of experts discussing health transformation in the post-pandemic world.
The AHA urged the Centers for Medicare & Medicaid Services to revise and reissue recent proposed regulations streamlining prior authorization requirements within certain coverage programs; consider additional regulations to limit care delays; and conduct oversight and enforcement for plans who…
The Agency for Healthcare Research and Quality seeks input through Nov. 12 on scientific evidence to inform a systematic review of telehealth use during COVID-19.
The Department of Health and Human Services’ Health Sector Cybersecurity Coordination Center (HC3) issued a monthly bulletin that consolidates a wide range of cyber security alerts from across government on the latest cybersecurity trends and threats, including guidance on hardening remote access…
The Centers for Disease Control and Prevention updated the list of underlying medical conditions that put adults of any age at higher risk for severe COVID-19 based on the latest scientific evidence.
The Department of Health and Human Services has renewed the COVID-19 public health emergency declaration for another 90 days effective Oct. 18.
This year’s AHA Dick Davidson NOVA Award honorees from CommonSpirit Health, Luminis Health, Memorial Health System, Providence, and Texas Health Resources will discuss their award-winning programs to address homelessness, an aging population, behavioral health and substance use, lagging community…
The National Institutes of Health awarded a total of $78 million in funding to develop and manufacture 12 new rapid diagnostic tests for SARS-CoV-2, with the goal of bringing to market as soon as this year new home and point-of-care tests that can detect multiple respiratory infections.